Equities Analysts Offer Predictions for SGMT Q1 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Sagimet Biosciences in a report released on Wednesday, March 11th. HC Wainwright analyst B. Folkes expects that the company will earn ($0.52) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.52) EPS and FY2030 earnings at $0.99 EPS.

SGMT has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Sagimet Biosciences in a research note on Thursday, January 22nd. Barclays started coverage on Sagimet Biosciences in a report on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 price objective for the company. Guggenheim initiated coverage on Sagimet Biosciences in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $27.00 price objective for the company. Finally, Wall Street Zen upgraded Sagimet Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Sagimet Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $26.00.

Sagimet Biosciences Price Performance

NASDAQ:SGMT opened at $5.21 on Friday. The firm has a market capitalization of $169.44 million, a price-to-earnings ratio of -3.32 and a beta of 3.35. The business has a 50 day simple moving average of $5.73 and a 200-day simple moving average of $6.62. Sagimet Biosciences has a 1 year low of $1.73 and a 1 year high of $11.41.

Sagimet Biosciences (NASDAQ:SGMT) last released its quarterly earnings results on Wednesday, March 11th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.14.

Institutional Investors Weigh In On Sagimet Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of SGMT. Royal Bank of Canada raised its position in Sagimet Biosciences by 819.2% during the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock worth $29,000 after buying an additional 4,391 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Sagimet Biosciences during the fourth quarter worth $30,000. Wedmont Private Capital acquired a new position in Sagimet Biosciences during the fourth quarter valued at $60,000. Virtu Financial LLC purchased a new stake in Sagimet Biosciences in the fourth quarter valued at $62,000. Finally, Hamilton Lane Advisors LLC acquired a new stake in Sagimet Biosciences during the 4th quarter worth about $66,000. Institutional investors and hedge funds own 87.86% of the company’s stock.

Insider Transactions at Sagimet Biosciences

In other Sagimet Biosciences news, CEO David Happel sold 12,101 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $5.36, for a total transaction of $64,861.36. Following the transaction, the chief executive officer owned 677,621 shares in the company, valued at approximately $3,632,048.56. This represents a 1.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 14.70% of the company’s stock.

Sagimet Biosciences News Roundup

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $29 price target, signaling continued bull case from the firm despite the cuts to some forecasts. HC Wainwright Research Note (summary)
• Positive Sentiment: Wall Street Zen published an upgrade on SGMT (reported by American Banking News), providing an additional positive signal from another market source. Sagimet Biosciences Upgraded at Wall Street Zen
• Neutral Sentiment: HC Wainwright slightly raised its FY2028 loss estimate (less negative: from ($3.30) to ($3.22)), a modest improvement but not a turnaround — suggests small model tweaks rather than material fundamental change. HC Wainwright FY2028 revision (summary)
• Negative Sentiment: HC Wainwright reduced several near- and mid‑term EPS forecasts: FY2027 worsened (from ($2.49) to ($2.62)), FY2029 was cut (from ($1.76) to ($1.87)), and quarterly FY2026 estimates were set as negative across Q1–Q4 (around ($0.50)–($0.54) per quarter). These downward revisions increase short‑term uncertainty and likely pressure the stock. HC Wainwright estimates and quarterly guidance (summary)

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.